3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Nasopharyngeal Carcinoma
59
Squamous Cell Carcinoma of Head and Neck
55
Head and Neck Neoplasms
55
Prostatic Neoplasms
40
Oropharyngeal Neoplasms
24
Carcinoma, Non-Small-Cell Lung
23
Carcinoma, Squamous Cell
21
Rectal Neoplasms
19
Breast Neoplasms
19
Nasopharyngeal Neoplasms
14
Neoplasm Metastasis
13
Glioblastoma
13
Carcinoma
13
Esophageal Neoplasms
12
Uterine Cervical Neoplasms
11
Pancreatic Neoplasms
11
Lung Neoplasms
11
Glioma
11
Esophageal Squamous Cell Carcinoma
11
Sarcoma
9
Radiation Injuries
8
Neoplasms
8
Laryngeal Neoplasms
8
Brain Neoplasms
8
Urinary Bladder Neoplasms
7
Tongue Neoplasms
7
Mouth Neoplasms
7
Hypopharyngeal Neoplasms
7
Carcinoma, Hepatocellular
6
Astrocytoma
6
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
Radiotherapy, Intensity-Modulated
×
Clear all
NCT06306170
2025-04-22
GYN-ART
IRCCS San Raffaele
Recruiting
1,000 enrolled